肠道微生物产生的代谢物phenylacetylglutamine在心力衰竭患者的预后值
W H Wilson Tang1,2, Ina Nemet1, Xinmin S Li1
1Center for Microbiome and Human Health, Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
European journal of heart failure
|December 21, 2023
概括
高水平的乙谷氨 (PAGln),一种肠道微生物代谢物,预测稳定心力衰竭 (HF) 患者的结果会更差. 升高的PAGln表明死亡率和住院风险增加,独立于其他因素.
科学领域:
- 代谢学 代谢学 代谢学
- 肠道微生物组研究研究
- 心血管疾病生物标志物 心血管疾病生物标志物
背景情况:
- 乙氨胺 (PAGln) 是一种由肠道微生物群从氨中衍生出的代谢物.
- PAGln已经证明了与心力衰竭 (HF) 相关的表型的机械联系.
- 在稳定的高风患者中,PAGln的预后价值需要进一步研究.
研究的目的:
- 为了研究血类甲基氨酸 (PAGln) 水平在患有稳定心力衰竭 (HF) 的患者的预后意义.
主要方法:
- 使用液体染色学-并联质谱法 (LC-MS/MS) 量化了禁食血PAGln水平.
- 分析了两个稳定的HF患者的大队伍 (克利夫兰和柏林).
- 评估的结果包括全因死亡率 (5年随访) 和HF住院或死亡率 (3年随访).
主要成果:
- 在克利夫兰队列中,PAGln水平升高与死亡风险显著增加有关 (最高与最低四分位数的调整HR为1.64 [1.07-2.53]).
- 在柏林队列中,较高的PAGln水平预测了HF住院或死亡的风险更高 (最高和最低四分位数的调整HR1.92 [1.02-3.61]).
- PAGln的预后值独立于传统的心脏风险因素,心标志物和三甲基胺N-氧化物水平.
结论:
- 高血PAGln水平与稳定的心力衰竭患者的不良临床结果有关.
- PAGln作为潜在的独立预后生物标志物用于心力衰竭.
- 对PAGln在HF病理生理学的作用进行进一步的研究是有必要的.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
94
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
94
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K